Patent Application
20230111578
The present disclosure relates to the field of respiratory viral pathogen testing. More specifically, the present invention is directed to a rapid mechanism and method for respiratory viral pathogen testing.
Conventionally, viral testing is aimed to identify a specific virus. In most situations, identifying a specific virus allows for the collection of epidemiological data and the opportunity for targeted treatment. For example, a patient diagnosed with a viral infection due to influenza might be provided with a prescription of antiviral medication.
However, for the vast majority of respiratory viruses, identifying the specific virus provides little benefit, as the treatment, including supportive care, does not change. As such, testing causes unnecessary cost and burden on the healthcare system. Similarly, there is currently little to no utility in screening asymptomatic individuals, outside of a pandemic or other unique situation.
In the setting of a pandemic, such as when a novel virus is involved, there is typically a lapse in development, production, and distribution of novel viral detection agents. This time delay allows for viral spread without epidemiologic data. Further complicating the scenario are asymptomatic carriers, such as with the recent COVID-19 pandemic. Identifying asymptomatic carriers has proven to be a unique challenge, and the lack of identification of asymptomatic carriers undoubtedly contributes to disease spread. For example, a person who is admitted to the hospital, without clinical evidence of a respiratory virus, might in fact be carrying, and spreading, the COVID-19 virus.
Due to testing limitations, including availability, cost, resource utilization, and time delay until test result, these individuals entering the hospital are typically not screened. They might be admitted to the hospital and spread the disease, unbeknownst to them and the numerous hospital employees they encounter. A similar scenario occurs even when cursory screening is deployed. For example, in the beginning of the COVID-19 pandemic people were being screened for the virus by answering a screening questionnaire and testing for the presence of a fever. This screening is low yield, especially when considering asymptomatic carriers. Innumerable scenarios such as the above could be described.
The present technology is directed to and addresses the issues identified above.
The present disclosure relates to a system and method for respiratory viral pathogen testing.
According to one aspect of the present disclosure, a rapid testing mechanism for respiratory viral pathogens includes a filter material positioned to capture exhaled breath particles from a respiratory tract. At least a portion of the filter material includes a pathogen binding adsorptive reagent, wherein the pathogen binding adsorptive reagent is a sulfated cellulose membrane. When the exhaled breath particles pass through the filter material, the following occur: when the binding adsorptive reagent reacts, a positive test for respiratory viral pathogens is indicated by the filter material; and when the pathogen binding adsorptive reagent does not react, a negative test for respiratory viral pathogens is individuated by the filter material.
According to another aspect of the present disclosure, a method of testing for respiratory viral pathogens includes providing at least a portion of a filter material with a pathogen binding adsorptive reagent, which is a sulfated cellulose membrane, and capturing exhaled breath particles from a respiratory tract with the filter material. A positive test for respiratory viral pathogens is indicated, by the filter material, when the pathogen binding adsorptive agent reacts. A negative test for respiratory viral pathogens is indicated, by the filter material, when the pathogen binding adsorptive reagent does not react.
According to another aspect of the present disclosure, a standalone detection device for respiratory viral pathogens includes a filter material supported by the standalone detection device. The standalone detection device is configured and positioned for detection of proximate exhaled breath particles from a respiratory tract of a mammal without physically contacting the mammal. At least a portion of the filter material includes a pathogen binding adsorptive reagent, wherein the pathogen binding adsorptive reagent is heparin sepharose or a sulfated cellulose membrane. When the exhaled breath particles pass through the filter material, the following occur: when the binding adsorptive reagent reacts, a positive test for respiratory viral pathogens is indicated by the filter material; and when the pathogen binding adsorptive reagent does not react, a negative test for respiratory viral pathogens is indicated by the filter material.
Yet another aspect of the present disclosure includes a standalone detection system for respiratory viral pathogens. A filter material is supported by the standalone detection system. The standalone detection system is configured and positioned for detection of proximate exhaled breath particles from a respiratory tract of a mammal without physically contacting the mammal. At least a portion of the filter material includes a pathogen binding adsorptive reagent, wherein the pathogen binding adsorptive reagent is heparin sepharose or a sulfated cellulose membrane. When the exhaled breath particles pass through the filter material, the following occur: when the binding adsorptive reagent reacts, a positive test for respiratory viral pathogens is indicated by the filter material using a first color; and when the pathogen binding adsorptive reagent does not react, a negative test for respiratory viral pathogens is indicated by the filter material using a second color. The standalone detection system also includes a photodetector positioned to detect the first color or the second color and transmit an indication of the positive test or the negative test based on the detected first color or second color.
Yet another aspect of the present disclosure includes a standalone detection system for respiratory viral pathogens. A filter material is supported by the standalone detection system. The standalone detection system is configured and positioned for detection of proximate exhaled breath particles from a respiratory tract of a mammal without physically contacting the mammal. At least a portion of the filter material includes a pathogen binding adsorptive reagent, wherein the pathogen binding adsorptive reagent is heparin sepharose or a sulfated cellulose membrane. When the exhaled breath particles pass through the filter material, the following occur: when the binding adsorptive reagent reacts, a positive test for respiratory viral pathogens is indicated by the filter material using a first barcode configuration; and when the pathogen binding adsorptive reagent does not react, a negative test for respiratory viral pathogens is indicated by the filter material using a second barcode configuration. The standalone detection system also includes an optical scanner positioned to detect the first barcode or the second barcode and transmit an indication of the positive test or the negative test based on the detected first barcode configuration or second barcode configuration.
Like reference numbers and designations in the various drawings indicate like element.
Before the present methods, implementations, and systems are disclosed and described, it is to be understood that this invention is not limited to specific synthetic methods, specific components, implementation, or to particular compositions, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular implementations only and is not intended to be limiting.
As used in the specification and the claims, the singular forms “a, “an” and “the” include plural references unless the context clearly dictates otherwise. Ranges may be expressed in ways including from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another implementation may include from the one particular value. Another implementation may include from the one particular value and/or the other particular value. Similarly, when values are expressed as approximations, for example by use of the antecedent “about,” it will be understood that the particular value forms another implementation. It will be further understood that the description includes instances where said event or circumstance occurs and instances where it does not.
The present disclosure relates generally to a rapid testing mechanism for respiratory viral pathogens. As shown in
Typically, the filter material 14 is made up of multiple layers of material. For example, the filter material 14 may be a three-ply material including a melt-blown polymer, such as polypropylene, polyethylene, or vinyl, between non-woven fabric. Numerous factors, such as, for example, shape, size, thickness, number of layers, materials used, fit, breathability, filtering capabilities, disposability, etc. may all be considered, and may vary depending on the application. Additional layers may provide more filtration; however, different materials provide different filtering. Various alternatives to face masks 12 may also be used in combination with the teachings of the present disclosure.
The face mask 12, or an alternative, may be positioned to capture exhaled breath particles from a respiratory tract of a mammal. For example, the face mask 12 may be positioned to cover the mouth and nose of the mammal and capture breath particles in one or more layers of the filter material 14. According to an exemplary embodiment, a layer closest to the source of the exhaled breath particles may be a filter. Some household items may work as a filter layer in a homemade mask, including, for example, paper products that you can breathe through, such as coffee filters, paper towels, and toilet paper. As described above, various structures, materials and configurations may be incorporated into the present disclosure.
Knowing the average size of a virus is about 20-400 nanometers (0.02-0.04 microns), the filter material 14 may capture particles greater than about 400 nanometers (0.4 micrometers). This may allow viruses or viral particles to pass through the filter 14. For example, the novel coronavirus is approximately 0.12 micrometers, so the novel coronavirus would pass freely through the filter material 14, but a bacteria that is 0.2 micrometers would be stopped by the filter material 14. However, most viral particles do not travel independently, but are carried by larger media, such as water droplets, that would be stopped by the filter. This filtering method is provided for exemplary purposes only and other filtering methods may be used. Further, one or more of the filtering methods may be implemented to narrow the viral pathogens that are detected.
At least a portion of the filter material 14 and/or another layer and/or another material is impregnated with or includes a pathogen binding adsorptive reagent. According to exemplary embodiments, the pathogen binding adsorptive reagent may be heparin Sepharose or sulfated cellulose, which may have a pore size of ≥0.4 micron. Although the amounts of the reagent may vary, according to an exemplary embodiment wherein the reagent is a liquid, the filter material 14 may be impregnated with 0.3 mL of the pathogen binding adsorptive reagent.
According to some embodiments, heparin-based porous adsorptive beads are combined with glycerine to slow the drying and extend viability. Further, the housing structure for the filter may be packaged in a porous polymeric membrane.
When the face mask 12 is analyzed, if the binding adsorptive reagent reacts, a positive test for the respiratory viral pathogens is indicated by the filter material 14, as shown at 16 in
If the pathogen binding reagent does not react, a negative test for respiratory viral pathogens is indicated by the filter material 14, as shown in
In addition to the filtering, the disclosure utilizes affinity chromatography to signify the presence of a virus or viral particles, regardless of the speciation. Non-viral material that is less than 400 nanometer may pass through the filter but will not react with the reagent. This is a low cost, highly sensitive, and qualitative test that is not labor intensive, not prone to operator variation (i.e., correct placement of nasopharyngeal swabs), or reliant on expensive, advanced technology. This technology could be available for home or commercial testing or healthcare point of care testing. The design would allow it to be deployed in resource poor countries. This test may have other novel implications, such as screening mammals (humans or animals) for the presence of contagious diseases before boarding aircraft, within closed spaces, or other places where there might be an increased risk of disease transmission, irrespective of a pandemic state. As stated above, the filter is not restricted to use with a face mask. For example, the filter may be positioned within an aircraft, classroom, office etc. to detect a presence of the virus.
The standalone detection device 30 may include a housing 36 or other component for supporting the filter material 14 described above. The standalone detection device 30 embodiment may be useful in environments such as, offices, planes, classrooms, etc., which may be somewhat contained environments.
A positive test may indicate the presence of a virus in the atmosphere and possible exposure. This will help mitigate spread, especially as people return without masks to school, office, etc.
The filter material 14 of the present embodiment may include the same capabilities as those described above with respect to the face mask 12, and may include, as a pathogen binding adsorptive reagent, heparin sepharose or a sulfated cellulose membrane.
The standalone detection system 40 may also include a detection device 42, which may be, for example, a photodetector positioned to detect the first color or the second color, or other similar indicators, and transmit an indication of the positive test or the negative test based on the detected first color or second color. The photodetector (42) may, wirelessly or otherwise, transmit the test indication, especially a positive test indication, for conveyance and display of the test indication.
According to another exemplary embodiment, the detection device 42 may be an optical scanner. Rather than colors indicating a positive test or a negative test, barcodes having different configurations, may be used to indicate a positive or negative test. The optical scanner (42) may be positioned to detect a first barcode configuration, indicating a positive test, or a second barcode configuration, indicating a negative test, and transmit an indication of the positive test or the negative test based on the first barcode configuration or the second barcode configuration. The barcodes may be dynamic, in that the lines or patterns can change based on reaction of the pathogen binding adsorptive reagent.
An environment for utilizing the standalone detection system 40 may include, for example, an HVAC or air purification system, which may be a location or position that is not easily visible. As such, the detection device 42 may read and signify the positive test or negative test. In the HVAC or air purification system environment, the filter material 14 may be positioned upstream and/or downstream of an air intake or other area of greater airflow F which may force viral particles onto the binding substrate. In some cases, the filter material 14 may be positioned upstream and/or downstream of the air intake to test the efficacy of the filter material 14.
The present disclosure provides a quick and accurate means for detecting viruses that are aerosolized or expelled from the respiratory tract during breathing, coughing, or sneezing. The disclosure exploits commonalities in the composition of viruses expelled from the respiratory tract of a mammal.
Benefits of the disclosure also include the provision of a rapid qualitative assessment for respiratory viral pathogens, which disregards speciation in the immediacy. Using this highly sensitive, rapid, and qualitative assessment for respiratory viral pathogens, regardless of speciation, could assist in implementing proper triage, proper precautions could be taken, and more specific testing could be imposed, if indicated.
Particular embodiments of the subject matter have been described. Other embodiments are within the scope of the following claims.
This patent application is a continuation-in-part of co-pending U.S. patent application Ser. No. 17/500,126, filed on Oct. 13, 2021, which is incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 17500126 | Oct 2021 | US |
| Child | 17895807 | US |
